Form 8-K · Current Report · Filed 2025-05-06
Halozyme Reports Strong Q1 2025 Results and Raises Financial Guidance
Halozyme Therapeutics, Inc. reported strong financial results for the first quarter of 2025, with total revenue increasing 35% year-over-year to $265 million and net income rising 54% to $118 million. The company also announced a new $250 million share repurchase program and raised its 2025 financial guidance, projecting total revenue to grow between 18% and 26% and adjusted EBITDA to increase by 25% to 33%. Royalty revenue, driven by growth in its blockbuster brands and recently launched products, increased 39% to $168 million. Non-GAAP diluted EPS grew 41% to $1.11. Halozyme also provided an update on its patent infringement lawsuit against Merck and recent corporate and partner activities.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-25-000025
- CIK
- 0001159036
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$60.62
Next session
+15.7%
Since filing
+81.9%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
Exhibits (1)
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.